trending Market Intelligence /marketintelligence/en/news-insights/trending/p30Hpd_ByVcz_NaoYGM1HA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Fitch affirms J&J's ratings on consistent operating, financial performance

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Fitch affirms J&J's ratings on consistent operating, financial performance

Fitch Ratings affirmed Johnson & Johnson's long-term issuer-default rating at AAA and its short-term issuer default rating at F1+, with a stable outlook.

The ratings actions reflect the company's consistent operating and financial performance supported by a diverse business portfolio of healthcare industry-leading positions, namely in pharmaceuticals, medical devices and consumer health.

Johnson & Johnson has been constantly generating positive free cash flow on the back of relatively stable revenues, strong margins and continued focus on cost control through conservative financial policies. The company is also expected to reduce its gross debt leverage through debt reduction and EBITDA growth.

The Brunswick, N.J.-based company's long-term growth is expected to be driven by innovation in combination with its internal research and development efforts and external collaborations and acquisitions.

Johnson & Johnson is expected to continue deploying cash for growth and dividends and may increase share repurchases when potential investment returns for growth-related transactions become less attractive.

The rating agency anticipates that the company will achieve low single-digit revenue growth in 2019 and continue focusing on cost controls in the near term.